Meeting
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Constance Thibault
European George Pompidou Hospital, Paris, France
Constance Thibault , Jean-Christophe Eymard , Anne-Claire Hardy-Bessard , Alison J. Birtle , Michael Krainer , Giulia Baciarello , Aude Flechon , Sylvestre Le Moulec , Dominique Spaeth , Brigitte Laguerre , Orazio Caffo , Jean-Laurent Deville , Philippe Beuzeboc , Ali Hasbini , Marine Gross-Goupil , Carole Helissey , Mostefa Bennamoun , Stephane Oudard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5033)
DOI
10.1200/JCO.2017.35.15_suppl.5033
Abstract #
5033
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2014 Genitourinary Cancers Symposium
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Antoine Angelergues
First Author: Elena Castro